Hong Kong stock sudden change | Kangfong Biological (09926.HK) rose more than 10% in the morning, with the first patient in the phase III clinical trial of Evovesi therapy for the treatment of colorectal cancer.

According to the Zhidao Finance mobile app, Kangfang Biology (09926.HK) rose more than 10% in the morning, as of the time of publication, it increased by 10.24% to HK$138.9, with a trading volume of HK$1.506 billion.